Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod
Executive Summary
The US FDA gave the drug a broad label in adults with indolent SM, without restrictions for disease severity or prior treatment, and Blueprint sees a potential $1.5bn market opportunity.
You may also be interested in...
Blueprint’s Evolution On Its Path To Financial Sustainability
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Blueprint Presents Positive Ayvakit Data, But Commercial Debate Could Continue
Detailed data in indolent systemic mastocytosis show improvement across primary and key secondary endpoints, but analysts pointed to lower improvement on symptoms outside of those affecting the skin.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.